CDKN2A and head and neck squamous cell carcinoma: However, in patients with p16-positive disease, afatinib failed to display an advantage in enhancing PFS.439 Therefore, it is necessary to examine the p16 status of R/M-HNSCC before giving afatinib treatment to guarantee patients’ benefits.